Mark Treherne

Mark joined NuVision in 2018 as Chairman bringing with him over 25 years of industrial R&D experience in the discovery and development of treatments for diseases with unmet need.

Mark began his research career with a PhD in Pharmacology from the University of Cambridge, followed by research with Pfizer and the setting up of life sciences software company, Cambridge Drug Discovery (CDD) as Chief Executive, sold as BioFocus in 2001.

Mark was Chairman of the non-profit ERBI (now One Nucleus) for 3 years, representing biotechnology companies in the East of England, and Chief Executive of the Life Sciences Organisation of UK Trade and Investment until 2016.

Mark has authored over 70 articles in the scientific and trade press.